Zacks Research Issues Positive Forecast for Cencora Earnings

Cencora, Inc. (NYSE:COR - Free Report) - Equities research analysts at Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for Cencora in a report issued on Wednesday, May 28th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings of $3.77 per share for the quarter, up from their prior forecast of $3.74. The consensus estimate for Cencora's current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora's Q4 2025 earnings at $3.78 EPS, FY2025 earnings at $15.70 EPS, Q1 2026 earnings at $4.02 EPS, Q3 2026 earnings at $4.40 EPS, Q4 2026 earnings at $4.03 EPS, FY2026 earnings at $17.22 EPS and FY2027 earnings at $18.99 EPS.

Other equities analysts have also issued research reports about the company. UBS Group upped their price target on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Robert W. Baird upped their price target on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Evercore ISI boosted their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Citigroup boosted their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 price objective on Cencora in a report on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Trading Up 0.3%

Shares of Cencora stock traded up $0.80 during trading hours on Friday, hitting $291.49. The company's stock had a trading volume of 3,890,003 shares, compared to its average volume of 1,537,835. Cencora has a twelve month low of $218.65 and a twelve month high of $309.35. The firm has a fifty day moving average of $284.83 and a 200-day moving average of $258.61. The stock has a market cap of $56.50 billion, a price-to-earnings ratio of 41.46, a P/E/G ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.80 earnings per share.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently added to or reduced their stakes in the company. Net Worth Advisory Group boosted its position in shares of Cencora by 1.4% in the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after buying an additional 36 shares during the period. Obermeyer Wealth Partners boosted its position in shares of Cencora by 1.3% in the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after buying an additional 36 shares during the period. Cromwell Holdings LLC boosted its position in shares of Cencora by 9.5% in the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after buying an additional 39 shares during the period. Pinnacle Wealth Management Advisory Group LLC boosted its position in shares of Cencora by 2.7% in the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock worth $435,000 after buying an additional 41 shares during the period. Finally, Whittier Trust Co. boosted its holdings in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after purchasing an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,223 shares of company stock worth $12,369,767 in the last quarter. 10.80% of the stock is owned by insiders.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.75%. The ex-dividend date is Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.